Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00 at JPMorgan Chase & Co.

Xenon Pharmaceuticals (NASDAQ:XENE) had its target price upped by equities research analysts at JPMorgan Chase & Co. from $77.00 to $80.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 45.36% from the stock’s current price.

A number of other research firms have also recently weighed in on XENE. Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a research report on Monday, March 9th. Guggenheim reissued a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wolfe Research assumed coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target for the company. Wedbush reduced their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. Finally, Needham & Company LLC reduced their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $75.69.

Xenon Pharmaceuticals Stock Down 1.3%

NASDAQ:XENE traded down $0.75 during mid-day trading on Tuesday, reaching $55.04. 75,721 shares of the stock were exchanged, compared to its average volume of 1,253,781. The company has a 50 day simple moving average of $55.09 and a 200-day simple moving average of $46.80. The stock has a market capitalization of $5.32 billion, a P/E ratio of -11.74 and a beta of 0.65. Xenon Pharmaceuticals has a 1 year low of $28.19 and a 1 year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the company posted ($0.83) EPS. As a group, research analysts predict that Xenon Pharmaceuticals will post -4.83 EPS for the current year.

Insider Activity

In other news, insider Christopher John Kenney sold 1,410 shares of Xenon Pharmaceuticals stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the sale, the insider owned 7,069 shares of the company’s stock, valued at $390,420.87. The trade was a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ian Mortimer sold 7,308 shares of Xenon Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $403,620.84. Following the completion of the sale, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. This represents a 26.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 296,707 shares of company stock valued at $17,845,365 over the last quarter. Company insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of XENE. Goldman Sachs Group Inc. boosted its holdings in Xenon Pharmaceuticals by 7.9% in the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after purchasing an additional 32,486 shares during the last quarter. Jump Financial LLC bought a new position in Xenon Pharmaceuticals in the 2nd quarter worth approximately $532,000. Sei Investments Co. bought a new position in Xenon Pharmaceuticals during the 2nd quarter valued at $711,000. The Manufacturers Life Insurance Company bought a new position in Xenon Pharmaceuticals during the 2nd quarter valued at $816,000. Finally, Alliancebernstein L.P. boosted its stake in Xenon Pharmaceuticals by 14.2% during the 2nd quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after purchasing an additional 189,141 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across multiple periods for Xenon Pharmaceuticals, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, while reiterating a Buy rating and a $74 price target. The higher estimates suggest improved expectations for the company’s long-term earnings trajectory. HC Wainwright raised Xenon estimates
• Positive Sentiment: Recent coverage also pointed to positive X-TOLE2 data and an extended cash runway, which can reduce financing concerns and support the stock’s valuation. Positive X-TOLE2 data and cash raise article
• Neutral Sentiment: A separate article examined Xenon’s valuation after the Phase 3 X-TOLE2 success and extended cash runway, reinforcing the market’s focus on pipeline progress and longer-term commercialization potential. Valuation after Phase 3 X-TOLE2 success article
• Neutral Sentiment: Short-interest data showed 0 shares reported as of May 11, so there is no meaningful short-squeeze signal in the latest filing data.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.